Predicting peptide binding to Major Histocompatibility Complex molecules.

Autoimmun Rev

Discipline of Medicine, Central Clinical School, University of Sydney, NSW, 2006, Australia.

Published: June 2011

The Major Histocompatibility Complex (MHC) constitutes an important part of the human immune system. During infection, pathogenic proteins are processed into peptide fragments by the antigen processing machinery. These peptides bind to MHC molecules and the MHC-peptide complex is then transported to the cell membrane where it elicits an immune response via T-cell binding. Understanding the molecular mechanism of this process will greatly assist in determining the aetiology of various diseases and in the design of effective drugs. One of the most challenging aspects of this area of research is understanding the specificity and sensitivity of the binding process. An empirical approach to the problem is unfeasible as there are over 512 billion potential binding peptides for each MHC molecule. Computational approaches offer the promise of predicting peptide binding, thus dramatically reducing the number of peptides proceeding to experimental verification. Various bioinformatic approaches have been developed to predict whether or not a particular peptide will bind to a particular MHC allele. Currently, peptide binding prediction methods can be categorised into three major groups: motif- and scoring matrix-based methods, artificial intelligence- (AI-) based methods, and structure-based methods. The first two are sequence-based approaches and are generally based on common sequence motifs in peptides known to bind to MHC molecules. The structure-based approach concerns the structural features and the distribution of energy between the binding peptide and the MHC molecule. Although knowledge of the molecular structure of the MHC molecules is expected to lead to better predictions of peptide binding, the development of structure-based methods has been relatively slow compared to sequence-based methods. Comparisons of various methods showed that the best sequence-based methods significantly outperform structure-based methods. This may be improved by producing more structures and binding data desperately needed by many alleles, especially class II molecules. On the other hand, the large number of verification methods and indicators used by structure-based studies hinders critical evaluation of the methods. Adopting commonly used assessment procedures can demonstrate the relative performance of structure-based methods in a straightforward comparison with other methods. This review provides an overview of current methods for predicting peptide binding to the MHC, with a focus on structure-based methods, and explores the potential for future development in this area.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2011.02.003DOI Listing

Publication Analysis

Top Keywords

peptide binding
20
structure-based methods
20
methods
15
predicting peptide
12
bind mhc
12
mhc molecules
12
binding
10
major histocompatibility
8
histocompatibility complex
8
mhc
8

Similar Publications

protein design has advanced such that many peptide assemblies and protein structures can be generated predictably and quickly. The drive now is to bring functions to these structures, for example, small-molecule binding and catalysis. The formidable challenge of binding and orienting multiple small molecules to direct chemistry is particularly important for paving the way to new functionalities.

View Article and Find Full Text PDF

The angiopoietin (Ang)-Tie axis, critical for endothelial cell function and vascular development, is a promising therapeutic target for treating vascular disorders and inflammatory conditions like sepsis. This study aimed to enhance the binding affinity of recombinant Ang1 variants to the Tie2 and explore their therapeutic potential. Structural insights from the Ang1-Tie2 complex enabled the identification of key residues within the Ang1 receptor binding domain (RBD) critical for Tie2 interaction.

View Article and Find Full Text PDF

As the most prevalent subtype of lung cancer, lung adenocarcinoma (LUAD) is closely associated with angiogenesis, which is fundamental to its progression. ADAM8 (A disintegrin and metalloproteinase 8) is an enzyme associated with tumor invasion, while its implications in LUAD angiogenesis are a field that awaits exploration. A thorough investigation into the impacts of ADAM8 on LUAD angiogenesis could contribute to the development of therapeutic drugs for LUAD.

View Article and Find Full Text PDF

Tungsten disulphide nanosheet modulated fluorescent gold nanocluster immunoprobe for the detection of tau peptide: Alzheimer's disease biomarker.

Anal Methods

January 2025

Department of Chemistry, School of Physical and Mathematical Science, Research Centre, University of Kerala, Kariavattom Campus, Thiruvananthapuram, Kerala, 695581, India.

The neuronal tau peptide serves as a key biomarker for neurodegenerative diseases, specifically, Alzheimer's disease, a condition that currently has no cure or definitive diagnosis. The methodology to noninvasively detect tau levels from body fluids remains a major hurdle for a rapid and simple diagnostic approach. Thus, developing new detection methods for sensing tau protein levels is crucial.

View Article and Find Full Text PDF

Re-evaluation of Cyclic Peptide Binding to Neurotensin Receptor 1 by Shifting the Peptide Register during Synthesis.

ACS Med Chem Lett

January 2025

Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia.

The head-to-tail cyclic peptide [Arg-Lys-Pro-Tyr-Tle-Leu] (peptide , where Tle is l--Leu) has previously been reported to bind to neurotensin receptor 1 (NTS1) (pKi = 5.97). Upon seeking to reproduce this finding, we found that peptide did not have a measurable affinity for NTS1.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!